The use of empagliflozin (an SGLT-2 inhibitor) significantly reduces the risk of cardiovascular death in both people with and without diabetes, which prompts the use of this drug in people with diabetes infected with SARS-CoV-2 [85]. The gene discussed is SLC5A2; the disease is diabetes mellitus.